Norepinephrine Serotonin Receptor Blocker for Depression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants have limited efficacy and are associated with significant side effects, such as sexual dysfunction, weight gain, and cardiovascular issues, with a relatively slow onset of action, necessitating the development of more effective treatments for depressive disorders.
Innovation Solution
Development of novel norepinephrine and selective serotonin receptor blockers, represented by compounds of formula I, which are designed to provide a therapeutic effect similar to or superior to existing antidepressants like Mirtazapine while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antidepressants (SSRIs, TCAs, MAOIs) are used to treat depressive disorder, then they can provide some therapeutic effect, but they cause serious side effects such as sexual dysfunction, weight gain, and cardiovascular issues
Solution Approach 1:
The patent segments the antidepressant mechanism into two distinct receptor actions: blocking 5-HT2A receptors (which causes most side effects) and blocking 5-HT3 receptors (which provides additional therapeutic benefit). By selectively targeting specific serotonin receptor subtypes rather than all serotonin receptors, the compound achieves therapeutic effects while minimizing adverse reactions associated with broad-spectrum serotonin antagonism.
Solution Approach 2:
The compound exhibits differential affinity for different serotonin receptor subtypes, with selective blockade of 5-HT2A and 5-HT3 receptors. This local quality approach means the drug has varying potency at different receptor sites, allowing therapeutic action at beneficial receptors while avoiding harmful effects at other serotonin receptor subtypes, thereby resolving the contradiction between efficacy and side effects.
2Reliability
If current antidepressants are used, then they can treat depressive symptoms, but the onset of therapeutic effect is slow (4-8 weeks)
Solution Approach 1:
The compound performs preliminary action by immediately blocking 5-HT3 receptors, which are involved in anxiety and agitation symptoms. This preliminary blockade provides rapid symptomatic relief for anxiety and agitation within hours to days of administration, while the broader antidepressant effect develops over time through 5-HT2A receptor blockade and downstream neuroadaptive changes.
Solution Approach 2:
The dual receptor blockade mechanism ensures continuous useful action: 5-HT2A receptor blockade provides sustained antidepressant effects over time, while concurrent 5-HT3 receptor blockade provides continuous anxiolytic and anti-agitant effects. This continuous multi-target action eliminates the lag period typically seen with conventional antidepressants.
3Reliability
If conventional antidepressants are used, then they can provide mood elevation, but they cause anxiety and exercise-induced agitation as significant side effects
Solution Approach 1:
The patent converts the potentially harmful 5-HT3 receptor activity into a beneficial effect. By adding 5-HT3 receptor blockade to the treatment mechanism, the compound transforms what could be a source of side effects into a therapeutic advantage, providing anxiolytic and anti-agitant effects that directly counterbalance any anxiety or agitation that might arise from serotonin modulation.
Data Source
AI summary
The present invention relates to a norepinephrine and selective serotonin receptor blocker and the use thereof. The norepinephrine and selective serotonin receptor blocker is a compound of formula I, or isomers, pharmaceutically acceptable salts or solvates thereof, wherein R1 is selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, C6-10 aralkyl, C6-10 arylalkoxy, C1-6 haloalkyl and C1-6 haloalkoxy; and R2 is one or more groups each independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, nitro, cyano, amino, hydroxyl, C1-6 haloalkyl, and C1-6 haloalkoxy. R3 is one or more groups each independently selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, nitro, cyano, amino, hydroxyl, C1-6 haloalkyl, and C1-6 haloalkoxy. The compound of the present invention is effective norepinephrine and selective serotonin receptor blocker.